financetom
Business
financetom
/
Business
/
Uber unveils US shuttle service, expands Costco tie-up to woo price-conscious users
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber unveils US shuttle service, expands Costco tie-up to woo price-conscious users
May 15, 2024 8:17 AM

(Reuters) - Uber Technologies ( UBER ) is introducing a shuttle service in the U.S. and widening a delivery tie-up with membership-only retailer Costco as part of a series of initiatives unveiled on Wednesday to attract price-conscious consumers amid competition from rival Lyft ( LYFT ).

The initiatives were unveiled at the company's GO-GET annual event for new products and are meant to maintain growth at the ride-share and delivery giant after a strong 2023 that saw it reporting its first-ever annual profit.

The San Francisco, California-based company said it will allow Uber Shuttle users to reserve seats in advance on buses operating in high-traffic areas like airports, concerts, and sports events.

The company said it will also allow users to schedule shared rides and announced a student discount on its Uber One membership.

On the food delivery front, it said it will offer Costco members in the U.S. ordering through Uber Eats additional discounts on their orders and a standing offer for 20% off on the annual Uber One plan.

While Lyft ( LYFT ) doesn't provide shuttle services like Uber ( UBER ), it offers a Transit mode feature, enabling users to access schedules of nearby shuttles, trains, and ferries through its app.

In recent months, Lyft ( LYFT ) has intensified competition with Uber ( UBER ), eliminating surge pricing amid a resurgence in ride-share demand driven by employees returning to offices and holiday travel.

Analysts suggest that the North American market might be nearing maturity, prompting both companies to seek new avenues of growth, such as advertising and subscription services.

Fares of UberX and Lyft Standard ride-sharing products have largely remained unchanged over the past two years, according to market research firm YipitData.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer must face lawsuit over diversity fellowship program, US court rules
Pfizer must face lawsuit over diversity fellowship program, US court rules
Jan 10, 2025
(Reuters) - A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer ( PFE ) fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker. At the urging of the group Do No Harm, a 2-1 panel...
Ecolab Well-Positioned for Future Growth, Faces Short-Term Challenges, RBC Says
Ecolab Well-Positioned for Future Growth, Faces Short-Term Challenges, RBC Says
Jan 10, 2025
01:21 PM EST, 01/10/2025 (MT Newswires) -- Ecolab ( ECL ) is expected to achieve stable volume and pricing growth during 2025, keeping the cleaning supplies company on track for moderate improvement, though it may still fall slightly short of consensus expectations for the next 12 months, analysts at RBC Capital Markets said in an earnings preview. For Q4, RBC...
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Jan 10, 2025
01:19 PM EST, 01/10/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) shares were down more than 12% Friday after the company reported positive topline results from a phase 2 trial of investigational compound atumelnant for treating classic congenital adrenal yyperplasia, or CAH, and adrenocorticotropic hormone, or ACTH-dependent Cushing's syndrome. The study, which included 28 patients across three dose groups,...
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Jan 10, 2025
Calidi Biotherapeutics Inc ( CLDI ) shares are trading lower by 32% to 92 cents during Friday’s session after the company priced its public offering of 5 million shares of common stock at $0.85 per share, aiming to raise approximately $4.25 million in gross proceeds. The offering is set to close on January 10, pending customary closing conditions. Ladenburg Thalmann...
Copyright 2023-2026 - www.financetom.com All Rights Reserved